Cargando…
Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19
PURPOSE: To assess the outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) for rhino-orbital-cerebral-mucormycosis (ROCM) post-COVID-19, as an adjuvant to standard systemic antifungal therapy. METHODS: In this prospective cohort study involving ROCM patients with clinical/radiological orbi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702621/ https://www.ncbi.nlm.nih.gov/pubmed/36427099 http://dx.doi.org/10.1007/s10792-022-02591-0 |
_version_ | 1784839698058838016 |
---|---|
author | Shakrawal, Jyoti Sharma, Vidhu Goyal, Amit Kumar, Deepak Meena, Seema Tiwari, Sarbesh Jain, Vidhi Elhence, Poonam Soni, Kapil Choudhury, Bikram Bhatnagar, Kavita Garg, Mahendra Kumar Misra, Sanjeev |
author_facet | Shakrawal, Jyoti Sharma, Vidhu Goyal, Amit Kumar, Deepak Meena, Seema Tiwari, Sarbesh Jain, Vidhi Elhence, Poonam Soni, Kapil Choudhury, Bikram Bhatnagar, Kavita Garg, Mahendra Kumar Misra, Sanjeev |
author_sort | Shakrawal, Jyoti |
collection | PubMed |
description | PURPOSE: To assess the outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) for rhino-orbital-cerebral-mucormycosis (ROCM) post-COVID-19, as an adjuvant to standard systemic antifungal therapy. METHODS: In this prospective cohort study involving ROCM patients with clinical/radiological orbital involvement, 44 eyes with ROCM stage ≥ 3B received TRAMB for 7 consecutive days with liposomal Amphotericin-B (3.5 mg/ml) with a minimum clinical and radiological follow-up of 3 months. All patients received standard systemic antifungal therapy also as per institutional protocol. Data pertaining to demography, systemic status, clinical involvement, imaging, surgical/medical management were also recorded. Potential eyes for exenteration were excluded. Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author 12 Given name: [Mahendra Kumar ] Last name [Garg]. Also, kindly confirm the details in the metadata are correct.All author names are presented accurately. Details in the metadata are correct. Thank you. RESULTS: Forty-four eyes of 42 patients were included, out of which 30 had diabetes mellitus & 22 had received steroid/oxygen treatment during COVID-19 infection. Forty eyes showed improvement or stable disease on follow-up on radiology. Four eyes which showed progression of the disease in orbit were reaugmented with TRAMB. No patient required exenteration. Subconjunctival haemorrhage occurred in six eyes and temporary blurring of vision in four eyes after TRAMB which resolved spontaneously. CONCLUSION: TRAMB, as an adjuvant to standard systemic antifungal therapy, is associated with a significant reduction or stabilisation of orbital involvement. TRAMB should be considered as an adjuvant therapy for ROCM to reduce disease progression as well as to preserve globe or sight. It has a promising role in preventing potential orbital exenterations. |
format | Online Article Text |
id | pubmed-9702621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-97026212022-11-28 Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19 Shakrawal, Jyoti Sharma, Vidhu Goyal, Amit Kumar, Deepak Meena, Seema Tiwari, Sarbesh Jain, Vidhi Elhence, Poonam Soni, Kapil Choudhury, Bikram Bhatnagar, Kavita Garg, Mahendra Kumar Misra, Sanjeev Int Ophthalmol Original Paper PURPOSE: To assess the outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) for rhino-orbital-cerebral-mucormycosis (ROCM) post-COVID-19, as an adjuvant to standard systemic antifungal therapy. METHODS: In this prospective cohort study involving ROCM patients with clinical/radiological orbital involvement, 44 eyes with ROCM stage ≥ 3B received TRAMB for 7 consecutive days with liposomal Amphotericin-B (3.5 mg/ml) with a minimum clinical and radiological follow-up of 3 months. All patients received standard systemic antifungal therapy also as per institutional protocol. Data pertaining to demography, systemic status, clinical involvement, imaging, surgical/medical management were also recorded. Potential eyes for exenteration were excluded. Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author 12 Given name: [Mahendra Kumar ] Last name [Garg]. Also, kindly confirm the details in the metadata are correct.All author names are presented accurately. Details in the metadata are correct. Thank you. RESULTS: Forty-four eyes of 42 patients were included, out of which 30 had diabetes mellitus & 22 had received steroid/oxygen treatment during COVID-19 infection. Forty eyes showed improvement or stable disease on follow-up on radiology. Four eyes which showed progression of the disease in orbit were reaugmented with TRAMB. No patient required exenteration. Subconjunctival haemorrhage occurred in six eyes and temporary blurring of vision in four eyes after TRAMB which resolved spontaneously. CONCLUSION: TRAMB, as an adjuvant to standard systemic antifungal therapy, is associated with a significant reduction or stabilisation of orbital involvement. TRAMB should be considered as an adjuvant therapy for ROCM to reduce disease progression as well as to preserve globe or sight. It has a promising role in preventing potential orbital exenterations. Springer Netherlands 2022-11-24 2023 /pmc/articles/PMC9702621/ /pubmed/36427099 http://dx.doi.org/10.1007/s10792-022-02591-0 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Shakrawal, Jyoti Sharma, Vidhu Goyal, Amit Kumar, Deepak Meena, Seema Tiwari, Sarbesh Jain, Vidhi Elhence, Poonam Soni, Kapil Choudhury, Bikram Bhatnagar, Kavita Garg, Mahendra Kumar Misra, Sanjeev Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19 |
title | Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19 |
title_full | Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19 |
title_fullStr | Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19 |
title_full_unstemmed | Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19 |
title_short | Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19 |
title_sort | outcomes of transcutaneous retrobulbar amphotericin b (tramb) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (rocm) following covid-19 |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702621/ https://www.ncbi.nlm.nih.gov/pubmed/36427099 http://dx.doi.org/10.1007/s10792-022-02591-0 |
work_keys_str_mv | AT shakrawaljyoti outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT sharmavidhu outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT goyalamit outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT kumardeepak outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT meenaseema outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT tiwarisarbesh outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT jainvidhi outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT elhencepoonam outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT sonikapil outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT choudhurybikram outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT bhatnagarkavita outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT gargmahendrakumar outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 AT misrasanjeev outcomesoftranscutaneousretrobulbaramphotericinbtrambasanadjuvanttherapyforrhinoorbitalcerebralmucormycosisrocmfollowingcovid19 |